Myriad Genetic
MYGN2.86046.74% ( -2.510 )
Myriad Genetic (MYGN)
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncol...
- Open
- 3.100
- High
- 3.260
- Low
- 2.810
- Prev. Close
- 5.370
- Volume
- 15.16M
- Turnover
- 44.87M
- Avg Price
- 2.960
- Bid/Ask Ratio
- --
- Amplitude
- 8.38%
- 52wk High
- 8.590
- Volume Ratio
- 19.14
- Turnover Ratio
- 19.04%
Myriad Genetic Analyst Rating
View MoreForecast & Rating
Jul 31, 2026Price forecast
$5.75101.05%
Forecast & RatingHold
9analysts
- Strong buy11.11%
- Buy11.11%
- Hold55.56%
- Sell11.11%
- Strong sell11.11%
News
- Market Beat · 22 hours ago
Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year Low After Earnings Miss
- TradingView · 1 day ago, 07:11 AM
MYRIAD GENETICS INC 2026: Revenue $190.7M, EPS ($0.46) — 10-Q Summary
- benzinga_article · 1 day ago, 07:03 AM
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- benzinga_article · 1 day ago, 12:48 AM
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
- Tip Ranks · 1 day ago, 09:55 PM
Myriad Genetics: Q2 Miss, Guidance Cut Lead to Lower $4 Price Target and Maintained Hold Rating
- Quartr · 2 days ago, 05:12 PM
MYGN: Q2 revenue declined 11% year-over-year, prompting lower 2026 guidance and operational changes
